TIDMPRX

RNS Number : 8965D

Proximagen Group PLC

23 May 2012

23 May 2012

Proximagen Group plc

Appointment of Nominated Adviser and Broker

London, UK, 23 May 2012 - Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on the treatment of disorders of the central nervous system and inflammatory diseases, announces the appointment of Cenkos Securities plc as its Nominated Adviser and Broker with immediate effect.

Enquiries

 
  Proximagen Group plc                           Tel: +44 (0)20 
                                                       7400 7700 
   Kenneth Mulvany, Chief Executive 
    Officer 
   James Hunter, Finance Director 
 
   Cenkos Securities plc (Nominated               Tel: +44 (0)20 
    Adviser and Broker)                                7397 8900 
   Bobbie Hilliam 
 
   M:Communications (Media enquiries)             Tel: +44 (0)20 
                                                       7920 2330 
   Mary-Jane Elliott / Sarah            proximagen@mcomgroup.com 
    Macleod / Hollie Vile

About Proximagen

Proximagen Group plc (AIM:PRX) is a European biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and inflammation.

The Company is developing potential new best-in-class therapeutics in its core disease areas including epilepsy, Parkinson's disease, and Alzheimer's disease, as well as in other areas such as inflammation, oncology and neuropathic pain.

Proximagen has a number of existing partnerships with pharmaceutical companies including GlaxoSmithKline, Upsher-Smith and Lundbeck, and is developing a broad pipeline of drug candidate programmes, with four programmes in clinical development and more than ten earlier stage assets being progressed.

Proximagen's strategy is to advance its pipeline with its partners and to acquire innovative drug candidates that complement its pipeline, with the objective of scaling up its risk-mitigated operating model and generating sustainable profits.

For more information, please visit www.proximagen.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPSESEFEFESESI

Proximagen Neuroscience (LSE:PRX)
Historical Stock Chart
From May 2024 to May 2024 Click Here for more Proximagen Neuroscience Charts.
Proximagen Neuroscience (LSE:PRX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Proximagen Neuroscience Charts.